Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 11;13:897776. doi: 10.3389/fendo.2022.897776

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wu, He, Wu, Ji, Hou, Liu, Ge, Yu, Yu, Wei, Qian, Luo, Feng, Feng, Wang, Huo, Li, Xue and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Results for the primary outcomes compared with placebo. Treatments are presented according to their effect estimate compared with placebo. Effect sizes are presented as MD or OR with 95% CI's. MD, mean difference; OR, odds ratio. exenatide1, exenatide-2mcg; exenatide2, exenatide-5/10mcg; linagliptin1, linagliptin-1mg; linagliptin5, linagliptin-5mg. (A) the change in HbA1c from baseline of fixed effects model; (B) adverse events of patients of fixed effects model; (C) the change in HbA1c from baseline of additive model; (D) adverse events of patients of additive model; (E) treatment ranking according to HbA1c of both models; (F) treatment ranking according to adverse events of both models.